DW News. . Since the patent for semaglutide, the key ingredient in weight loss drugs, expired in March, prices in India have fallen 80%. The country's GLP-1 market has expanded by a factor of ten in just one year. #dwbusiness
Semaglutide just got a massive price cut in India. The patent expired in March and prices for this popular GLP-1 peptide have crashed by 80%. For anyone following peptide research, this is the kind of market shift you rarely see.
facebook.com
“DW News. . Since the patent for semaglutide, the key ingredient in weight loss drugs, expired in March, prices in India have fallen 80%. The country's GLP-1 market has expanded by a factor of ten in just one year. #dwbusiness facebook.com”
Here’s what actually matters: with semaglutide now off-patent, researchers and compounders in India suddenly have a ton more access. The GLP-1 research market in the country ballooned tenfold in just twelve months. That’s not a typo. Ten times the action in one year.
Why is this a big deal? Lower cost means more research. More research means more data, more innovation, and more real-world feedback on how semaglutide and other GLP-1 peptides perform in a variety of settings.
Breakdown:
80% drop in price opens the doors for independent labs and smaller research groups
Market expansion lets suppliers scale up, which means more consistent quality and wider sourcing options
Expect more Indian vendors to show up on the global scene — check the vendor directory if sourcing is on your radar
Key takeaway: semaglutide isn’t just a high-ticket peptide for big pharma anymore. The research community in India is about to start publishing more, innovating faster, and pushing boundaries with GLP-1 peptides.
Want to dig into the science or see what’s available? Start with the semaglutide page for compound details and research context.
India’s GLP-1 market just became the world’s testbed for semaglutide research. Expect the ripple effects to keep coming.
Related Reading
Saitama University researchers discover that a natural peptide aptamer switches between two target proteins depending on metal ions
News · Eur J Vasc Endovasc SurgThe STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · EIN PresswirePeptide Therapeutics Market Revenue To Cross $222 Billion By 2030 Supported By Rising Demand
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.